Market Newsdesk

Blue Apron to Participate in the Morgan Stanley Technology, Media and Telecom Conference on March 1

NEW YORK–(BUSINESS WIRE)–
Blue Apron Holdings, Inc. (NYSE: APRN) announced today that it will participate in the Morgan Stanley Technology, Media and Telecom Conference on Monday, March 1, 2021. Blue Apron Chief Executive Officer Linda Findley Kozlowski and Chief Financial Officer Randy Greben will conduct a virtual fireside chat at 8:45 a.m. ET and will also meet with institutional investors in virtual one-on-one and group meetings throughout the day.

A live webcast of the virtual fireside chat will be available online on Blue Apron’s Investor Relations website at investors.blueapron.com (select “Events & Presentations”). A replay of the webcast will be available for 90 days following the live event at investors.blueapron.com (select “Events & Presentations”).

If you have questions about Blue Apron or are interested in conducting a conference call or meeting with management, please contact the company’s investor relations firm, JCIR, at (212) 835-8500 or via email at [email protected].

About Blue Apron

Blue Apron’s vision is “better living through better food.” Launched in 2012, Blue Apron offers fresh, chef-designed recipes that empower home cooks to embrace their culinary curiosity and challenge their abilities to see what a difference cooking quality food can make in their lives. Through its mission to spark discovery, connection and joy through cooking, Blue Apron continuously focuses on bringing incredible recipes to its customers, while minimizing its carbon footprint, reducing food waste, and promoting diversity and inclusion.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005365/en/

Investor Contact

[email protected]

Joseph Jaffoni, Richard Land, James Leahy

JCIR

[email protected] or 212-835-8500

Media Contact

Muriel Lussier

Blue Apron

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Luxury Technology Women Other Technology Men Specialty Food/Beverage Consumer Retail Online Retail

MEDIA:

Logo

MedCerts Partners with Equus to Upskill Jobseekers Nationwide

Partnership will develop non-traditional apprenticeships in healthcare and IT across 10 states

LIVONIA, Mich.–(BUSINESS WIRE)–MedCerts, a leader in online career certification training, is partnering with Equus Workforce Solutions, a comprehensive provider of workforce development services, to connect employers with healthcare and IT apprentices.

Having helped over 25,000 students gain credentials for new careers since 2009, MedCerts provides resources for employers – with whom Equus has relationships in major metro areas across Louisiana, Texas, Pennsylvania, Ohio, Kentucky, Georgia, Michigan, Virginia and California – to fill vacancies, host internships and externships, and coordinate informal opportunities for students to shadow industry professionals and gain hands-on volunteer experience.

MedCerts and Equus are excited to offer training and registered apprenticeship opportunities in high demand occupations, with a goal to help 60 career seekers enroll in registered apprenticeship programs by September.

“This partnership is a perfect example of synergy,” said Sandy Mead, National Director of Workforce Development at MedCerts. “We give students the ability to reskill for critical industry positions, and Equus will help connect our students with the employers most in need of these skills.”

Acquired by Stride, Inc. (NYSE: LRN) in 2020, MedCerts engages students in online, hands-on career training courses in healthcare, medical, and IT fields to prepare for over twenty national certifications. More than 1,000 organizations have hired MedCerts students or offer training and employment opportunities for students and employees, including CVS Pharmacy, Walmart, and the American Red Cross.

“Equus is uniquely positioned to connect career seekers to training and employment opportunities. When students’ skills can be matched to strategic apprenticeships and employment opportunities, it creates a win-win scenario for all parties,” said Michelle Day, National Workforce Solutions Director at Equus. “We’re very excited to be working with MedCerts to help our business partners meet their skills needs and streamline the employment process.”

For more information about MedCerts or to apply, visit https://medcerts.com/.

About MedCerts

MedCerts – a Stride company – is a national online training provider strengthening the workforce through innovative eLearning solutions. Focused on certifications in high-demand areas of Allied Healthcare and IT, it serves individuals from all backgrounds, including the military and their families, career changers and the under- and unemployed. MedCerts delivers certification and career training through HD-quality video-based instruction, virtual simulations, games and animations, and on-the-job training through experiential learning solutions. Since 2009, the company has developed over 35 career programs, trained and up-skilled more than 25,000 individuals across the country and partnered with over 500 American job centers and more than 1,000 healthcare organizations have MedCerts trained employees on staff. MedCerts was acquired by Stride, Inc. in 2020. Stride has transformed the teaching and learning experience for millions of people by providing innovative, high-quality, tech-enabled education solutions, curriculum, and programs directly to students, schools, the military, and enterprises in primary, secondary, and post-secondary settings. For more information, visit medcerts.com.

About Equus Workforce Solutions

Equus Workforce Solutions, formerly ResCare Workforce Services, is the nation’s leading and most comprehensive provider of workforce development services in North America. Our 50+ year legacy of experience encompasses the development, design, and delivery of demand-driven workforce solutions. A dedicated and passionate team of more than 2,500 workforce professionals put the industry’s best practices to work across more than 350 North American locations, assisting over 1.6 million job seekers and thousands of employers annually. Equus Workforce Solutions is the largest for-profit workforce development company in the United States. For more information, visit https://equusworks.com. Follow us on LinkedIn and Twitter.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005360/en/

Emily Riordan

Director, Corporate Communications

Stride, Inc.

[email protected]

KEYWORDS: United States North America Michigan

INDUSTRY KEYWORDS: Technology Human Resources Professional Services Other Education Internet Training Health General Health Education

MEDIA:

Logo

Odonate Therapeutics Announces Financial Results for the Three and Twelve Months Ended December 31, 2020

NEW YORK–(BUSINESS WIRE)–Odonate Therapeutics, Inc. (NASDAQ: ODT), a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer, today announced financial results for the three and twelve months ended December 31, 2020.

As of December 31, 2020, Odonate had $157.3 million in cash, compared to $180.5 million as of December 31, 2019. This decrease in cash resulted primarily from cash used in operating activities for the twelve months ended December 31, 2020 of $113.1 million, partially offset by the receipt of $87.4 million of net proceeds from Odonate’s September 2020 underwritten public offering. Odonate’s net loss for the three and twelve months ended December 31, 2020 was $32.3 million and $126.4 million, or $0.87 and $3.84 per share, respectively, compared to $27.9 million and $111.8 million, or $0.91 and $4.05 per share, respectively, for the same periods in 2019.

“Positive results of CONTESSA, Odonate’s Phase 3 study investigating tesetaxel as a potential treatment for patients with metastatic breast cancer, were recently presented at the 2020 San Antonio Breast Cancer Symposium,” said Kevin Tang, Chief Executive Officer of Odonate. “We continue to plan to submit a New Drug Application for tesetaxel to the FDA in mid-2021.”

About Tesetaxel

Tesetaxel is an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several properties that make it unique among taxanes, including: oral administration with a low pill burden; a long (~8-day) terminal plasma half-life in humans, enabling the maintenance of adequate drug levels with relatively infrequent dosing; no history of hypersensitivity (allergic) reactions; and significant activity against chemotherapy-resistant tumors. In patients with metastatic breast cancer (MBC), tesetaxel was shown to have significant, single-agent antitumor activity in two multicenter, Phase 2 studies. Tesetaxel currently is the subject of three studies in MBC, including a multinational, multicenter, randomized, Phase 3 study in patients with MBC, known as CONTESSA. Positive results of CONTESSA were presented at the 2020 San Antonio Breast Cancer Symposium in December.

About CONTESSA

CONTESSA is a multinational, multicenter, randomized, Phase 3 study of tesetaxel, an investigational, orally administered taxane, in patients with metastatic breast cancer (MBC). CONTESSA is comparing tesetaxel dosed orally at 27 mg/m² on Day 1 of a 21-day cycle plus a reduced dose of capecitabine (1,650 mg/m²/day dosed orally for 14 days of a 21-day cycle) to the approved dose of capecitabine alone (2,500 mg/m²/day dosed orally for 14 days of a 21-day cycle) in 685 patients randomized 1:1 with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)‑negative MBC previously treated with a taxane in the neoadjuvant or adjuvant setting. Capecitabine is an oral chemotherapy agent that is considered a standard-of-care treatment in MBC. Where indicated, patients must have been treated with endocrine therapy with or without a cyclin-dependent kinase (CDK) 4/6 inhibitor. The primary endpoint is progression-free survival (PFS) as assessed by an Independent Radiologic Review Committee (IRC). The secondary endpoints are overall survival (OS), objective response rate (ORR) as assessed by the IRC and disease control rate (DCR) as assessed by the IRC.

Positive results of CONTESSA were presented at the 2020 San Antonio Breast Cancer Symposium in December. The primary endpoint was met: median PFS was 9.8 months for tesetaxel plus a reduced dose of capecitabine versus 6.9 months for the approved dose of capecitabine alone, an improvement of 2.9 months. The risk of disease progression or death was reduced by 28.4% (hazard ratio=0.716 [95% confidence interval [CI]: 0.573‑0.895; p=0.003]). Neutropenia was the most common Grade ≥3 treatment‑emergent adverse event.

About Odonate Therapeutics, Inc.

Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best‑in‑class therapeutics that improve and extend the lives of patients with cancer. Odonate’s initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Odonate’s goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality‑of‑life advantages over current alternatives. To learn more, please visit www.odonate.com.

Forward-looking Statements

This press release contains “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995. We caution investors that forward-looking statements are based on management’s expectations and assumptions as of the date of this press release and involve substantial risks and uncertainties that could cause the actual outcomes to differ materially from what we currently expect. These risks and uncertainties include, but are not limited to, those associated with: expectations regarding the outcome of CONTESSA, our Phase 3 study of tesetaxel in patients with metastatic breast cancer; expectations regarding the enrollment, completion and outcome of our other clinical studies; expectations regarding the timing for our planned New Drug Application submission for tesetaxel; expectations regarding the timing of a regulatory decision on tesetaxel and our ability to obtain regulatory approval of tesetaxel; the unpredictable relationship between preclinical study results and clinical study results; and other risks and uncertainties identified in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements in this press release apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.

ODONATE THERAPEUTICS, INC. Balance Sheets (in thousands, except par value and share amounts)
		December 31,				December 31,
		2020				2019
Assets
Current assets:
Cash		$	157,265			$	180,460
Prepaid expenses and other current assets			2,607				3,468
Total current assets			159,872				183,928
Property and equipment, net			2,286				1,663
Right-of-use lease assets			4,017				1,581
Restricted cash			714				714
Other			997				941
Total assets		$	167,886			$	188,827
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable		$	14,168			$	15,583
Accrued expenses			12,247				8,881
Lease liabilities, current portion			658				315
Total current liabilities			27,073				24,779
Lease liabilities, less current portion			4,668				1,748
Total liabilities			31,741				26,527
Stockholders’ equity:
Common stock, $0.01 par value—100,000,000 shares authorized; 38,562,281 and 32,050,906 shares issued and outstanding at December 31, 2020 and December 31, 2019, respectively			367				300
Additional paid-in capital			502,205				402,077
Accumulated deficit			(366,427	)			(240,077	)
Total stockholders’ equity			136,145				162,300
Total liabilities and stockholders’ equity		$	167,886			$	188,827

ODONATE THERAPEUTICS, INC. Statements of Operations (in thousands, except share and per share amounts)
		Three Months Ended								Twelve Months Ended
		December 31,								December 31,
		2020				2019				2020				2019
Operating expenses:
Research and development		$	30,075			$	25,853			$	117,041			$	104,034
General and administrative			2,359				2,856				10,392				10,896
Total operating expenses			32,434				28,709				127,433				114,930
Loss from operations			(32,434	)			(28,709	)			(127,433	)			(114,930	)
Other income, net			148				858				1,083				3,105
Net loss		$	(32,286	)		$	(27,851	)		$	(126,350	)		$	(111,825	)
Net loss per share:
Basic and diluted		$	(0.87	)		$	(0.91	)		$	(3.84	)		$	(4.05	)
Weighted-average shares outstanding:
Basic and diluted			37,287,893				30,564,258				32,862,552				27,625,468

ODONATE THERAPEUTICS, INC. Statements of Cash Flows (in thousands)
		Year Ended
		December 31,
		2020				2019
Cash flows from operating activities:
Net loss		$	(126,350	)		$	(111,825	)
Adjustments to reconcile net loss to net cash used in operating activities:
Equity-based compensation expense			9,828				11,444
Depreciation and amortization			445				426
Non-cash lease expense			425				634
Loss on disposal of property and equipment			83				–
Changes in operating assets and liabilities:
Prepaid expenses and other assets			763				(2,936	)
Accounts payable			(1,415	)			4,782
Accrued expenses			3,366				1,516
Lease liabilities			(275	)			(679	)
Net cash used in operating activities			(113,130	)			(96,638	)
Cash flows from investing activities:
Purchases of property and equipment			(432	)			(166	)
Net cash used in investing activities			(432	)			(166	)
Cash flows from financing activities:
Proceeds from issuance of common stock, net of issuance costs			87,383				135,096
Proceeds from issuance of common stock under employee stock plans			2,984				3,581
Net cash provided by financing activities			90,367				138,677
Net (decrease) increase in cash and restricted cash			(23,195	)			41,873
Cash and restricted cash, beginning of period			181,174				139,301
Cash and restricted cash, end of period		$	157,979			$	181,174
Supplemental disclosure of cash flow information:
Initial recognition of right-of-use lease assets		$	2,861			$	2,215
Tenant improvement allowance		$	719			$	–
Property and equipment purchases included in accounts payable		$	1			$	24

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005353/en/

Odonate Therapeutics, Inc.

Michael Hearne

Chief Financial Officer

(332) 208-7611

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Pharmaceutical Health Oncology Clinical Trials

MEDIA:

Logo

Ruth’s Hospitality Group, Inc. to Announce Fourth Quarter and Full Year 2020 Financial Results on March 5, 2021

WINTER PARK, Fla.–(BUSINESS WIRE)–
Ruth’s Hospitality Group, Inc. (Nasdaq: RUTH) today announced that it will host a conference call to discuss fourth quarter and full year 2020 financial results on Friday, March 5, 2021 at 8:30 AM Eastern Time. A press release with fourth quarter and full year 2020 financial results will be issued at approximately 7:00 AM Eastern Time that same day.

The conference call can be accessed live over the phone by dialing 201-689-8470. A replay will be available one hour after the call and can be accessed by dialing 412-317-6671; the password is 13716005. The replay will be available until Friday, March 12, 2021. The call will also be webcast live from the Company’s website at www.rhgi.com under the Investor Relations section.

About Ruth’s Hospitality Group

Ruth’s Hospitality Group, Inc., headquartered in Winter Park, Florida, is the largest fine dining steakhouse company in the U.S. as measured by the total number of Company-owned and franchisee-owned restaurants, with over 140 Ruth’s Chris Steak House locations worldwide specializing in USDA Prime grade steaks served in Ruth’s Chris’ signature fashion – “sizzling.”

For information about our restaurants or to purchase gift cards, please visit www.RuthsChris.com. For more information about Ruth’s Hospitality Group, Inc., please visit www.rhgi.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005320/en/

Investor Relations Contact

Fitzhugh Taylor

Email: [email protected]

KEYWORDS: United States North America Florida

INDUSTRY KEYWORDS: Retail Restaurant/Bar Food/Beverage

MEDIA:

Posted on February 23, 2021 8:33 am

Simulations Plus and the University of Pittsburgh Drug Discovery Institute Receive SBIR Grant Funding for Large Molecule Safety Collaboration

Simulations Plus and the University of Pittsburgh Drug Discovery Institute Receive SBIR Grant Funding for Large Molecule Safety Collaboration

Computational Modeling, Human Liver Microphysiology Systems (MPS) and the MPS-Database Platforms to be Integrated for Safety Testing

LANCASTER, Calif.–(BUSINESS WIRE)–
Simulations Plus, Inc. (Nasdaq: SLP), a leading provider of modeling and simulation software and services for pharmaceutical safety and efficacy, today announced that its DILIsym Services (DSS) division and the University of Pittsburgh Drug Discovery Institute (UPDDI) have jointly received a Phase I NIH-funded SBIR grant to combine the highly successful DSS software (DILIsym) and UPDDI’s vLAMPS experimental liver model and the microphysiology systems database (MPS-Db) to predict the safety of large (macro) molecules such as proteins that are increasingly used to treat diseases. The first phase of development funded by the grant will include beta version software construction and vLAMPS testing of several large molecules captured in the MPS-Db. Successful completion of the objectives will lead to an application for a larger Phase II grant, which would fully fund the development of the joint commercial offering.

DSS coordinates the DILI-sim Initiative, which is a public-private partnership that has guided development of the DILIsym® software package. This software uses properties of drugs to predict their risk of causing liver injury in patients, and is now widely used to support key drug development decisions. To date, this approach has been successfully applied to traditional small molecule drugs. Similarly, the UPDDI has developed the vLAMPS and MPS-Db technologies for other drug development applications. The focus on large molecule safety in an integrated fashion represents an important new direction for both organizations, allowing them to support development of safer large molecule therapeutics.

Dr. Paul B. Watkins, the Director of the Institute for Drug Safety Sciences at University of North Carolina and chair of the Scientific Advisory Board of the DILI-sim Initiative, said: “Large molecules, such as monoclonal antibodies, have become the hottest target for drug development. However, these therapeutics are not without liver safety liabilities that are currently very hard to predict. I believe that this collaboration, which received very high priority for funding, will help solve this problem.”

Dr. Brett A. Howell, President of DILIsym Services, added: “The development of novel therapeutics involving larger and more complex molecules is ever-increasing. This collaboration will allow DSS to remain at the forefront of drug safety prediction innovation and expand our product offerings.”

Dr. D. Lansing Taylor, Director of the UPDDI, Distinguished Professor and Allegheny Foundation Professor of Computational and Systems Biology, stated: “The integration of our biomimetic human liver MPS (vLAMPS) with the MPS-Db and DILIsym computational modeling is a powerful application of quantitative systems pharmacology (QSP) to large molecule safety and will advance large molecule safety testing.”

About Simulations Plus, Inc.

Simulations Plus, Inc., is a leading provider of modeling and simulation software and consulting services supporting drug discovery, development research, and regulatory submissions. With our subsidiaries, Cognigen, DILIsym Services, and Lixoft, we offer solutions which bridge machine learning, physiologically based pharmacokinetics, quantitative systems pharmacology/toxicology, and population PK/PD modeling approaches. Our technology is licensed and applied by major pharmaceutical, biotechnology, chemical, consumer goods companies and regulatory agencies worldwide. For more information, visit our website at www.simulations-plus.com.

The DILIsym Services division of Simulations Plus has developed DILIsym^® and NAFLDsym^® QSP software, and is developing IPFsym™ and RENAsym™ QSP software, to provide the pharmaceutical industry with the tools and resources to efficiently develop safe and effective drug therapies. DILIsym and RENAsym are designed to address drug-induced liver injury (DILI) and drug-induced acute kidney injury, respectively. NAFLDsym and IPFsym are designed for target or compound evaluation of therapeutic efficacy in nonalcoholic fatty liver disease (NAFLD or NASH) and idiopathic pulmonary fibrosis (IPF), respectively. More information is available on the company’s web page.

About the University of Pittsburgh Drug Discovery Institute (UPDDI)

The UPDDI applies QSP and human MPS to understand the mechanisms of disease progression, as well as to predict potential therapeutics for diseases such as non-alcoholic fatty liver disease (NAFLD), type 2 diabetes, cancer and neurodegenerative diseases, and to identify mechanisms of toxicology.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995 – With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. Words like “believe,” “expect,” and “anticipate” mean that these are our best estimates as of this writing, but that there can be no assurances that expected or anticipated results or events will actually take place, so our actual future results could differ significantly from those statements. Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain our competitive advantages, acceptance of new software and improved versions of our existing software by our customers, the general economics of the pharmaceutical industry, our ability to finance growth, our ability to continue to attract and retain highly qualified technical staff, our ability to identify and close acquisitions on terms favorable to the Company, and a sustainable market. Further information on our risk factors is contained in our quarterly and annual reports and filed with the U.S. Securities and Exchange Commission.

Follow us on Twitter | LinkedIn | YouTube

View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005305/en/

Simulations Plus Investor Relations

Ms. Renee Bouche

661-723-7723

[email protected]

Hayden IR

Mr. Cameron Donahue

651-653-1854

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Data Management Health Technology Software Pharmaceutical Biotechnology

MEDIA:

Logo

Heritage Global Inc. Completes Buy Now Pay Later (BNPL) Debt Sales

SAN DIEGO–(BUSINESS WIRE)–
Heritage Global Inc. (Nasdaq: HGBL) (“Heritage Global,” “HGI” or “the Company”), an asset services company specializing in financial and industrial asset transactions, today announced that its financial asset sales division, National Loan Exchange (NLEX), has successfully closed the sale of a $25 million portfolio of BNPL charged-off accounts.

According to Dave Ludwig, President of Heritage Financial Assets, “We believe that BNPL has the potential to achieve sales growth at levels similar to FinTech assets for our NLEX division. The current stay-at-home economy that has resulted from Covid-19 restrictions has produced increased online shopping activity which has driven rapid growth of BNPL sales, and as a result, we are seeing increasing charge-off inventories of these assets in the U.S.

“Debt buyers are already showing significant interest in this new sector, as reflected by the large number of qualified bidders that participated in the process for this sale, as well as the ultimate price accepted,” continued Ludwig. “BNPL, with origins in the EU and Australia, has quickly become a significant purchasing option for online consumers in the U.S., creating increased sales opportunities for merchants. As BNPL volume grows, it makes sense to expect that a certain amount of charge-offs will follow. NLEX is competitively positioned to provide an effective and efficient debt sale process between new BNPL issuers and our group of highly vetted buyers.”

About Heritage Global Inc. (www.heritageglobalinc.com)

Heritage Global Inc. (NASDAQ: HGBL) is an asset services company specializing in financial and industrial asset transactions. The company provides a full suite of services including market making, acquisitions, dispositions, valuations and secured lending. Heritage Global focuses on identifying, valuing, acquiring and monetizing underlying tangible and intangible assets across twenty-eight global sectors. The company acts as an adviser, as well as a principal, acquiring or brokering turnkey manufacturing facilities, surplus industrial machinery and equipment, industrial inventories, accounts receivable portfolios, intellectual property, and entire business enterprises.

Forward-Looking Statements

This communication includes forward-looking statements based on our current expectations and projections about future events. For these statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. While the Company believes the forward-looking statements contained in this communication are accurate, these forward-looking statements represent the Company’s beliefs only as of the date of this communication, and there are a number of factors that could cause actual events or results to differ materially from those indicated by such forward-looking statements, including variability in magnitude and timing of asset liquidation transactions, the impact of changes in the U.S. national and global economies, and interest rate and foreign exchange rate sensitivity, as well as other factors beyond the Company’s control. Unless required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In light of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements, which speak only as of the date of this release. For more details on factors that could affect these expectations, please see our filings with the Securities and Exchange Commission.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005253/en/

Company Contact:

Scott West

Chief Financial Officer

Heritage Global Inc.

858/847-0656

Investor Relations Contact:

John Nesbett/Jennifer Belodeau

IMS Investor Relations

203/972.9200

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA:

Posted on February 23, 2021 8:33 am

Charles River Associates (CRA) Strengthens Energy Practice

Charles River Associates (CRA) Strengthens Energy Practice

BOSTON–(BUSINESS WIRE)–Charles River Associates (NASDAQ: CRAI), a worldwide leader in providing economic, financial, and management consulting services, today announced David Walls has joined as a Vice President in its Energy Practice. Mr. Walls will be based in CRA’s Boston office.

Mr. Walls has more than 40 years of experience advising clients on energy industry transformation, business growth strategies, emerging technologies and business strategy. He specializes in clean energy, renewables, decarbonization and grid modernization. Mr. Walls works with utilities, equipment manufacturers, investors, and government institutions to assess and position for power industry policy and regulatory trends, new technologies, and market opportunities.

Mr. Walls has assisted companies in developing smart grid business case studies and investment plans, independent power subsidiaries, and energy service and distributed generation businesses. He also advises energy clients on strategic partnerships, raising capital, and due diligence supporting M&A transactions. Mr. Walls has also worked closely with government organizations, such as the U.S. Department of Energy, New York State Energy Research and Development Authority, and the California Energy Commission to develop and implement advanced energy technology programs related to smart grid, distributed generation, storage, electric vehicles, and advanced energy systems.

“David is a great addition to our team,” said CRA’s Energy Practice Leader Chris Russo. “His knowledge of transformation and development in the energy space will provide additional breadth to how we help our clients grow and move forward.”

“We’re pleased to welcome David and further add to our strong Energy expertise in the U.S.,” said CRA’s Chairman, President and Chief Executive Officer Paul Maleh.

Prior to joining CRA, Mr. Walls was a Managing Director with the Energy Practice at Navigant Consulting, Inc. (now Guidehouse), where he was a member of the Practice Leadership team. He was also a senior member of the Emerging Energy Technology Practice at Arthur D. Little.

Mr. Walls holds a master’s degree in Mechanical Engineering from the Massachusetts Institute of Technology.

About CRA’s Energy Practice

CRA’s Energy Practice blends decades of industry knowledge with world-class economic and analytical expertise. Investors, executives, and litigators from across the energy sector have turned to CRA for expert advice in hundreds of successful engagements. CRA’s expertise is grounded in a comprehensive understanding of the energy sector, including electricity and gas markets, litigation and regulatory support, market analytics and strategy, energy asset and enterprise valuation, and energy trading and risk management.

About Charles River Associates (CRA)

Charles River Associates® is a leading global consulting firm specializing in economic, financial, and management consulting services. CRA advises clients on economic and financial matters pertaining to litigation and regulatory proceedings, and guides corporations through critical business strategy and performance-related issues. Since 1965, clients have engaged CRA for its unique combination of functional expertise and industry knowledge, and for its objective solutions to complex problems. Headquartered in Boston, CRA has offices throughout the world. Detailed information about Charles River Associates, a registered trade name of CRA International, Inc., is available at www.crai.com. Follow us on LinkedIn, Twitter, and Facebook.

SAFE HARBOR STATEMENT

Statements in this press release concerning the addition of David Walls, CRA’s Energy Practice, future business David Walls may generate for CRA and statements using the terms “strengthen,” “grow” or similar expressions are “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. These statements are based upon management’s current expectations and are subject to a number of factors and uncertainties. Information contained in these forward-looking statements is inherently uncertain, and actual performance and results may differ materially due to many important factors. Such factors that could cause actual performance or results to differ materially from any forward-looking statements made by CRA include, among others, the failure to generate engagements for us; dependence on the growth of our litigation or strategy consulting practice, including in energy services; the potential loss of clients; the demand environment; global economic conditions; foreign exchange rate fluctuations; and intense competition, as well as other potential factors that could affect our financial results are included in our periodic filings with the Securities and Exchange Commission, including those under the heading “Risk Factors.” We cannot guarantee any future results, levels of activity, performance, or achievement. We undertake no obligation to update any forward-looking statements after the date of this press release, and we do not intend to do so.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005197/en/

Media Relations

CRA International

[email protected]

617-425-6453

Nicholas Manganaro

Sharon Merrill Associates, Inc.

[email protected]

617-542-5300

KEYWORDS: United States North America Massachusetts

INDUSTRY KEYWORDS: Professional Services Other Energy Legal Energy Finance Consulting

MEDIA:

Logo

 Cambridge Global Payments and ZipLingo Announce New Strategic Partnership

 Focused on building an enhanced international payments solution for the Direct Selling Industry

TORONTO–(BUSINESS WIRE)–
Cambridge Global Payments (“Cambridge”), a FLEETCOR company (NYSE: FLT) and a provider of integrated cross-border payments and currency risk management solutions, and ZipLingo a provider of integrated business solutions to help direct selling companies increase revenues and brand awareness, are pleased to announce they have partnered to develop an enhanced international payments solution targeted at the direct selling industry.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210223005075/en/

This partnership will deliver a strong payment solution within ZipLingo’s digital wallet, allowing payout in more than 145 different currencies, with local deposits available in certain countries and regions. In addition, this enhanced solution can be tailored to each customer’s specific needs.

“We’re incredibly excited about our integrated partnership with ZipLingo, as our combined capabilities offer a completely new and refreshing way to provide payee optionality, while improving the overall user experience for independent consultants “ said Frank Mannarino, VP, Channels & Alliances, Cambridge Global Payments. “The solution stack powered by Cambridge offers payment delivery to over 200 countries, in over 145 currencies, which will enable direct selling organizations the ability to seamlessly pay their field commissions anywhere around the globe, while removing the administrative burden and friction that are typically associated with cross-border money movement.”

“We’re thrilled to be working with Cambridge to improve our digital wallet user experience. Cambridge has been able to increase our global reach to payout in more countries and currencies than we ever thought possible,” said Matt Marchbanks. “These improved capabilities will allow us to offer our direct selling clients payment technology that cannot be matched.”

About Cambridge Global Payments

Cambridge Global Payments, a FLEETCOR company, is a leading provider of integrated cross-border payment services and currency risk management solutions. As a trusted partner for more than 25 years, Cambridge delivers innovative solutions designed to mitigate foreign exchange exposure and address unique business needs. Our award-winning capabilities and industry-leading technologies simplify the way businesses connect with the global marketplace. As one of the largest bank-independent providers globally, we are flexible and responsive, with offices and applicable licensing and regulatory approvals across North America, Europe, and Australia. Learn more at cambridgefx.com and follow us on Twitter and LinkedIn.

About ZipLingo

Creating a company or brand experience attracts and keeps passionate distributors. Part of that connection is a strong and dynamic interface through technology. The best companies attract and engage their distributors with multifunctional tools to operate their business. Founded in 2008, ZipLingo has developed innovative direct selling digital tools to help organizations communicate, compensate, and support their independent consultants.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005075/en/

Cambridge:

Brad Loder

VP, Global Business Development and Marketing

647-627-6635

[email protected]

ZipLingo:

Matthew H. Marchbanks

President/CEO

(888) 245-3090 ext. 103

[email protected]

KEYWORDS: North America Canada

INDUSTRY KEYWORDS: Finance Banking Professional Services Technology Software

MEDIA:

Logo

Logo

Florida Department of Transportation Selects Iteris’ ClearGuide SaaS Solution to Provide Smart Mobility Infrastructure Management

Iteris’ Cloud-based Solution to Provide Traffic Signal Performance Measures and Mobility Intelligence for Key Arterials and Signalized Intersections Throughout Florida’s District 5

• ClearGuide, utilizing traffic data from HERE Technologies, provides real-time, historical and contextual transportation analytics to improve safety and mobility
• Mobility improvements will be made at key arterials and intersections throughout Florida’s District 5, which houses over 2,100 signalized intersections, representing 25% of signalized intersections in the state
• Three-year deal marks expansion of Iteris software-as-a-service solutions in Florida, a key geographic market

SANTA ANA, Calif.–(BUSINESS WIRE)–Iteris, Inc. (NASDAQ: ITI), the global leader in smart mobility infrastructure management, today announced that it has been awarded a three-year software-as-a-service (SaaS) contract from the Florida Department of Transportation (FDOT) District 5 for use of its ClearGuide™ solution to improve mobility throughout the central Florida district.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210223005121/en/

With real-time and historical traffic data from HERE Technologies – a global leader in mapping and location platform services – ClearGuide, which has been upgraded to include automated signal performance measures (ATSPM) capabilities, will enable the analysis and visualization of traffic data to improve roadway mobility and safety across Florida’s District 5, one of the fastest-growing areas in the state. District 5 covers nine counties – Brevard, Flagler, Lake, Marion, Orange, Osceola, Seminole, Sumter and Volusia – spanning nearly 9,000 square miles, with its more than four million residents logging over 125 million miles daily in the region. The district houses over 2,100 signalized intersections, representing 25% of signalized intersections in the state.

Under the terms of the three-year SaaS agreement, Iteris will provide powerful ClearGuide features, including: ATSPM capabilities to optimize signal performance, dynamic maps to support detailed traffic analysis; features to help identify and mitigate congestion; animations to analyze events and optimize response plans; historical trend reports and dynamic congestion charts to track reliability and support planning; and easy, customizable analysis of major Florida roadways. The ClearGuide solution is designed to grow and expand to meet the district’s future challenges, as well as ingest a wider range of information, such as data from connected and automated vehicles.

The ClearGuide solution is a key component of Iteris’ ClearMobility™ Platform, the world’s most complete solution to continuously monitor, visualize and optimize mobility infrastructure. ClearMobility applies cloud computing, artificial intelligence, advanced sensors, advisory services and managed services to help ensure roads are safe, travel is efficient, and communities thrive.

“We are thrilled to be able to support the district’s goal of better managing its transportation network by providing mobility intelligence, as well as 24/7 operations and signal maintenance and monitoring for 25% of the state of Florida’s signalization intersections,” said Scott Perley, vice president, Transportation Systems at Iteris. “ClearGuide enables users to receive regular, proactive recommendations through an intuitive user interface to ultimately improve efficiency at major intersections and throughout the wider network.”

About Iteris, Inc.

Iteris is the global leader in smart mobility infrastructure management – the foundation for a new era of mobility. We apply cloud computing, artificial intelligence, advanced sensors, advisory services and managed services to achieve safe, efficient and sustainable mobility. Our end-to-end solutions monitor, visualize and optimize mobility infrastructure around the world to help ensure that roads are safe, travel is efficient, and communities thrive. Visit www.iteris.com for more information and join the conversation on Twitter, LinkedIn and Facebook.

Iteris Forward-Looking Statements

This release may contain forward-looking statements, which speak only as of the date hereof and are based upon our current expectations and the information available to us at this time. Words such as “believes,” “anticipates,” “expects,” “intends,” “plans,” “seeks,” “estimates,” “may,” “should,” “will,” “can,” and variations of these words or similar expressions are intended to identify forward-looking statements. These statements include, but are not limited to, statements about the awarded contract and our ClearGuide solution and ClearMobility platform. Such statements are not guarantees of future performance and are subject to certain risks, uncertainties, and assumptions that are difficult to predict, and actual results could differ materially and adversely from those expressed in any forward-looking statements as a result of various factors.

Important factors that may cause such a difference include, but are not limited to, our ability to successfully deliver services timely and in a cost-effective manner; government funding and budgetary issues and delays; impact of influences and variances of general economic, political, environment, and other conditions in the markets we address; and the potential impact of product and service offerings from competitors and such competitors’ patent coverage and claims. Further information on Iteris, Inc., including additional risk factors that may affect our forward-looking statements, is contained in our Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q, our Current Reports on Form 8-K, and our other SEC filings that are available through the SEC’s website (www.sec.gov).

View source version on businesswire.com: https://www.businesswire.com/news/home/20210223005121/en/

Media Contact

David Sadeghi

Tel: (949) 270-9523

Email: [email protected]

Investor Relations

MKR Investor Relations, Inc.

Todd Kehrli

Tel: (213) 277-5550

Email: [email protected]

KEYWORDS: California Florida United States North America

INDUSTRY KEYWORDS: Technology Public Policy/Government Automotive General Automotive Public Transport Trucking Rail Engineering Transport State/Local Logistics/Supply Chain Management Manufacturing Other Automotive Networks Internet Mobile/Wireless Data Management

MEDIA:

Logo

Photo

Florida Department of Transportation Selects Iteris’ ClearGuide SaaS Solution to Provide Smart Mobility Infrastructure Management (Graphic: Business Wire)